**Supplementary Materials**

**A) IL-1β**




**Figure S1 A. IL-1β expression (200x, scale bar=100 µm). (a)** SEC-Control group showed marked immunostaining of IL-1β within the cytoplasm of the neoplastic cells (arrowheads). **(b)** SEC- SOR group showed a decrease in the immunoexpression of IL-1β expression within the neoplastic cells (arrowheads). **(c)** SEC-LYC group showed a decrease in the immunoexpression of IL-1β expression within the neoplastic cells (arrowheads). **(d)** SEC-SOR-LYC group showed a marked decrease in IL-1β expression within the neoplastic cells (arrowheads).

**B) Bcl-2**




**Figure S1 B. Bcl-2 expression (200x, scale bar=100 µm). (a)** SEC-Control group showed marked cytoplasmic immunoexpression of Bcl2 within (arrowheads). **(b)** SEC- SOR group showed a decrease in the immunoexpression of Bcl2 within the neoplastic cells (arrowheads). **(c)** SEC-LYC group showed a decrease in the immunoexpression of Bcl2 within the neoplastic cells (arrowheads). **(d)** SEC-SOR-LYC group showed a marked decrease in Bcl2 expression within the neoplastic cells (arrowheads).

C) **Ki-67**




**Figure S1 C. Ki-67 expression (200x, scale bar=100 µm). (a)** SEC-Control group showed marked immunostaining of Ki67 within the proliferated neoplastic cells (arrow). **(b)** SEC- SOR group showed a decrease in the Ki67 expression within the neoplastic cells (arrow). **(c)** SEC-LYC group showed a decrease in the Ki67 expression within the neoplastic cells (arrow). **(d)** SEC-SOR-LYC group showed a marked decrease in Ki67 expression within the proliferated neoplastic cells (arrow).

**D) Caspase 3**




**Figure S1 D. Caspase 3 expression (200x, scale bar=100 µm). (a)** SEC-Control group showed a marked decrease in the caspase 3 expression within the neoplastic cells (arrows). **(b)** SEC- SOR group showed a marked increase in caspase 3 expression (red arrows) within the proliferated neoplastic cells (black arrow). **(c)** SEC-LYC group showed an increase in caspase 3 expression (red arrows) within the proliferated neoplastic cells (black arrows). **(d)** SEC-SOR-LYC group showed a marked increase in caspase 3 expression (red arrows) within the proliferated neoplastic cells (black arrow).

**E) BAX**




**Figure S1 E. BAX expression (200x, scale bar=100 µm). (a)** SEC-Control group showed mild cytoplasmic and nuclear immunostaining of BAX expression within (arrowheads). **(b)** SEC-SOR group showed increased immunoexpression of BAX expression within the neoplastic cells (arrowheads). **(c)** SEC-LYC group showed increased immunoexpression of BAX expression within the neoplastic cells (arrowheads). (d) SEC-SOR-LYC group showed a marked increase in BAX expression within the neoplastic cells (arrowheads).

**F) P53**




**Figure S1 F. P53 expression (200x, scale bar=100 µm). (a)** SEC-Control group showed mild immunostaining of P53 expression within a few neoplastic cells (arrowheads). **(b)** SEC-SOR group showed an increase in immunoexpression of P53 within the neoplastic cells (arrowheads). **(c)** SEC-LYC group showed an increase in immunoexpression of P53 within the neoplastic cells (arrowheads). (d) SEC-SOR-LYC group showed a marked increase in P53 expression within the neoplastic cells (arrowheads).




**Figure S2. Immunohistochemical percent of positive area/8 HPF using Image-J software; version 1.54 D, Java 1.8,0_354 (NIH, USA) of (a) IL-1β, (b) Bcl2, (c) Ki-67, (d) Caspase 3, (e) BAX and (f) P53.** Data were expressed as mean ±SD ($n$ = 10). Tukey-Kramer multiple comparison tests were used after a one-way analysis of variance (ANOVA) of the data to examine and assess the findings. $^{*}$means significant versus the SEC-Control group, $^{a}$ means significant versus the SEC-SOR group, and $^{b}$means significant versus the SEC-LYC group. Each group differed significantly from the others at $p \leq 0.05$.